Skip to main content
Clinical Trials/NCT05945394
NCT05945394RecruitingNot Applicable

The Surem TRAF3IP2 Level and Atherosclerotic Plaque Development in Human

Nanjing Medical University1 site in 1 country800 target enrollmentStarted: September 1, 2023Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
800
Locations
1
Primary Endpoint
stenosis of coronary artery

Study Overview

Brief Summary

To evaluate the association of surem TRAF3IP2 levels with the atherosclerotic plaque development in human

Detailed Description

Previous study had concluded that TRAF3IP2 plays a causal role in atherosclerotic plaque development and vulnerability in mice. However, no human data was available. In the present study, patients who receive coronary angiography will be enrolled. Their surem TRAF3IP2 levels will be tested using ELASA. The association of surem TRAF3IP2 levels with the atherosclerotic plaque will be evaluated.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Cross Sectional

Eligibility Criteria

Ages
18 Years to 90 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients with suspected coronary heart disease
  • patients received coronary angiography

Exclusion Criteria

  • NYHA III-IV
  • malignant tumor
  • acute infection
  • thyroid dysfunction

Outcomes

Primary Outcomes

stenosis of coronary artery

Time Frame: 1 week

The stenosis of coronary artery based on the results of coronary angiography

Secondary Outcomes

  • coronary artery calcium(1 week)

Investigators

Sponsor
Nanjing Medical University
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Jin Geng

associate doctor

Nanjing Medical University

Study Sites (1)

Loading locations...

Similar Trials

The Surem TRAF3IP2 Level and... | Clinical Trial